Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 58

Sort by

Sort Order Select

Journal Articles

A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma

Karen L Burger, PhD, Mark B. Meads, PhD, Anders Berglund, Paula S. Oliveira, Allison Distler, Praneeth Reddy Sudalagunta, PhD, Timothy Jacobson, Jamie Teer, PhD, Eric A. Welsh, PhD, Hongyue Dai, PhD, John M. Koomen, PhD, Alugubelli Raghunandan Reddy, Gabriel De Avila, Alexandre Tungesvik, MD, William Roush, PhD, Ariosto Siqueira Silva, PhD, Kenneth H. Shain, MD PhD, John Cleveland, PhD

Blood (2019) 134 (Supplement_1): 5537.

https://doi.org/10.1182/blood-2019-130830

Published: 2019

Journal Articles

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

Takashi Ishio, Joji Shimono, Sarvesh Kumar, Yuquan Lin, Emmanuel Bachy, Michael N. Petrus, Yandan Yang, Michiyuki Maeda, Hideki Goto, Satoshi Hashino, Takanori Teshima, MD, Thomas A. Waldmann, MD, Louis Staudt, MD, Masao Nakagawa

Blood (2019) 134 (Supplement_1): 3781.

https://doi.org/10.1182/blood-2019-124670

Published: 2019

Journal Articles

The Distinctive Metabolic Environment of the Bone Marrow Niche Drives Leukemia Chemoresistance

Nick van Gastel, PhD, Jessica B. Spinelli, PhD, Azeem Sharda, MS, Amir Schajnovitz, PhD, Ninib Baryawno, PhD, Catherine S Rhee, PhD, Toshihiko Oki, MD PhD, Eliane Grace, Heather J. Soled, Charles Vidoudez, PhD, Sunia A. Trauger, PhD, Marcia C. Haigis, PhD, David T. Scadden, MD

Blood (2019) 134 (Supplement_1): 3725.

https://doi.org/10.1182/blood-2019-124789

Published: 2019

Journal Articles

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Lai N Chan, PhD, Mark A. Murakami, MDMA,MMSc, Rebecca Caesar, Christian Hurtz, PhD, Kohei Kume, PhD, Teresa Sadras, PhD, Seyedmehdi Shojaee, PhD, Petri Pölönen, MSc, Amol Ugale, PhD, Jaewoong Lee, PhD, Kadriye Nehir Cosgun, PhD, Huimin Geng, PhD, Merja Heinäniemi, PhD, Olli Lohi, MD PhD, Arun P. Wiita, MD PhD, Shai Izraeli, MD, David M Weinstock, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 3944.

https://doi.org/10.1182/blood-2019-130774

Published: 2019

Journal Articles

Integrating Enhancer Profiling and CRISPR Dropout Screen Revealed Selenoprotein Synthesis Pathway As a New Vulnerability in AML

Yajian Jiang, MBBS, Xiangguo Shi, PhD, Kenneth Eagle, Charles Y Lin, PhD, Daisuke Nakada, PhD

Blood (2019) 134 (Supplement_1): 639.

https://doi.org/10.1182/blood-2019-126904

Published: 2019

Journal Articles

Social Vulnerability Is Associated with Emergency Department Dependency in Pediatric Sickle Cell Disease Patients

Kristina Lai, MPH, Peter A. Lane, MD

Blood (2019) 134 (Supplement_1): 4680.

https://doi.org/10.1182/blood-2019-125351

Published: 2019

Journal Articles

Identify AMPK-Mediated Autophagy and Oxphos As a Novel Metabolic Vulnerability for Targeted Therapy in Mantle Cell Lymphoma

Yixin Yao, PhD, Yang Liu, MD, Hui Zhang, Angela Leeming, Joseph Mitchell McIntosh, Preetesh Jain, MBBS,MDDM,PhD, Liang Zhang, MD PhD, Krystle Nomie, PhD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 1506.

https://doi.org/10.1182/blood-2019-126738

Published: 2019

Journal Articles

Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials

Danielle Ulanet, Victor Chubukov, PhD, John Coco, BS, Gabrielle McDonald, PhD, Mya Steadman, BA, Rohini Narayanaswamy, MS, Sebastien Ronseaux, PhD, Sung Choe, PhD, Tabea Erdmann, PhD, Kevin Truskowski, BS, Kavitha Nellore, PhD, Siva Sanjeeva Rao, PhD, Hosahalli Subramanya, PhD, Georg Lenz, MD, Michael Cooper, MD, Josh Murtie, PhD, Kevin Marks, PhD

Blood (2019) 134 (Supplement_1): 1570.

https://doi.org/10.1182/blood-2019-123471

Published: 2019

Journal Articles

Protein Phase Separation in Hematopoietic Stem Cell Aging

Laure Maneix, PhD, Polina Iakova, M.S., Shannon Moree, B.A., Melanie Sweeney, B.A., Nagaishwarya Moka, MD, Sarvari Venkata Yellapragada, MD, Andre Catic, MD PhD

Blood (2019) 134 (Supplement_1): 5003.

https://doi.org/10.1182/blood-2019-124092

Published: 2019

Journal Articles

Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma

Eugenio Morelli, MD, Mariateresa Fulciniti, PhD, Mehmet Kemal Samur, PhD, Caroline Ribeiro, PhD, Leon Wert-Lamas, PhD, Annamaria Gulla, MD, Anil Aktas Samur, PhD, Cinzia Federico, PhD, Francesca Scionti, PhD, Yao Yao, PhD, Nicola Amodio, PhD, Giada Bianchi, MD, Yu-Tzu Tai, PhD, Pierfrancesco Tassone, MD, Kenneth C. Anderson, MD, Carl D. Novina, MD PhD, Massimo Loda, MD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 317.

https://doi.org/10.1182/blood-2019-130730

Published: 2019

Journal Articles

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Fiona Brown, BS, Yang Zhang, PhD, Claire Hinterschied, Alexander Prouty, BS, Shelby Sloan, BS, JoBeth Helmig-Mason, Msc, Ji Hyun Chung, PhD, Kris Vaddi, PhD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Lapo Alinari, MD PhD, Peggy Scherle, PhD, Rosa Lapalombella, PhD, Jihye Paik, PhD, Robert A Baiocchi, MD PhD

Blood (2019) 134 (Supplement_1): 302.

https://doi.org/10.1182/blood-2019-130797

Published: 2019

Journal Articles

Functional profiling to improve therapy in TCL

Kojo S. J. Elenitoba-Johnson

Blood (2019) 133 (6): 504–506.

https://doi.org/10.1182/blood-2018-12-889741

Published: 2019

Journal Articles

Retrospective Analysis of Outcomes in Acute Myeloid Leukemia (AML) Patients Exposed to Intravenous Contrast Prior to Stem Cell Transplantation

Gayathri Ravi, MD, Yazan Abou-Ismail, MD, Margaret Rothgery, Anjali Shekar, Sophie Golec, Marcos de Lima, MD, Ben Tomlinson, MD

Blood (2018) 132 (Supplement 1): 5179.

https://doi.org/10.1182/blood-2018-99-119293

Published: 2018

Journal Articles

PIG-a Gene Expression Deficiency Association with Reduced DNA Damage Checkpoint Response and Activation

Jeffrey J Pu, MD PhD, Shasha Lu, MD PhD, Matthew Nemesure, Emmanuel Kwame Teye, PhD, Emily Schleicher, George-Lucian Moldovan, PhD, Robert A. Brodsky, MD, Fangyuan Chen, MD PhD

Blood (2018) 132 (Supplement 1): 3875.

https://doi.org/10.1182/blood-2018-99-119177

Published: 2018

Journal Articles

Catabolic Flexibility Enhances Drug Resistance but Induces Selective Vulnerability to New Mitochondrial-Targeted Therapeutic Combinations in IDH Mutant Leukemia

Jean-Emmanuel Sarry, PhD, Christian Recher, MD PhD, Lucille Stuani, PhD, Jean-Charles Portais, PhD

Blood (2018) 132 (Supplement 1): 5238.

https://doi.org/10.1182/blood-2018-99-112523

Published: 2018

Journal Articles

Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of Mitochondrial Vulnerability in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 910.

https://doi.org/10.1182/blood-2018-99-114525

Published: 2018

Journal Articles

Mitochondrial Dysfunction in Normal and Malignant Hematopoiesis

Aaron Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): SCI-11.

https://doi.org/10.1182/blood-2018-99-109470

Published: 2018

Journal Articles

PRMT1 Mediated FLT3 Methylation As a Therapeutic Vulnerability in FLT3-ITD + AML

Blood (2018) 132 (Supplement 1): 760.

https://doi.org/10.1182/blood-2018-99-112766

Published: 2018

Journal Articles

Systems Biology Analysis Identifies Targetable Vulnerability Networks to Proteasome Inhibitors in Multiple Myeloma

Mark B. Meads, PhD, Rafael Renatino Canevarolo, PhD, Praneeth Reddy Sudalagunta, PhD, Paula S. Oliveira, Dario M. Magaletti, Bin Fang, PhD, Maria D Coelho Siqueira Silva, MSc, Amit Kulkarni, PhD, Hongyue Dai, PhD, William S. Dalton, PhDMD, Ion Petre, PhD, John M. Koomen, PhD, Ariosto Siqueira Silva, PhD, Kenneth H. Shain, MD PhD

Blood (2018) 132 (Supplement 1): 950.

https://doi.org/10.1182/blood-2018-99-120269

Published: 2018

Journal Articles

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Daniel Thomas, MD PhD, Yusuke Nakauchi, MD PhD, Manhong Wu, PhD, Ming Zheng, PhD, Subarna Sinha, PhD, David Dill, PhD, Gary Peltz, MD PhD, Ravindra Majeti, MD PhD

Blood (2018) 132 (Supplement 1): 440.

https://doi.org/10.1182/blood-2018-99-115040

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A CK1δ/CK1ε Regulated Metabolic Circuit Is a Therapeutic Vulnerability for Multiple Myeloma

Genome-Wide CRISPR Library Screening Identifies CDK6 As Genetic Vulnerability in Adult T-Cell Leukemia/Lymphoma

The Distinctive Metabolic Environment of the Bone Marrow Niche Drives Leukemia Chemoresistance

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Integrating Enhancer Profiling and CRISPR Dropout Screen Revealed Selenoprotein Synthesis Pathway As a New Vulnerability in AML

Social Vulnerability Is Associated with Emergency Department Dependency in Pediatric Sickle Cell Disease Patients

Identify AMPK-Mediated Autophagy and Oxphos As a Novel Metabolic Vulnerability for Targeted Therapy in Mantle Cell Lymphoma

Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials

Protein Phase Separation in Hematopoietic Stem Cell Aging

Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma

PRMT5 Inhibition Drives Therapeutic Vulnerability to BCL-2 Inhibition with Venetoclax and Provides Rationale for Combination Therapy in Mantle Cell Lymphoma

Functional profiling to improve therapy in TCL

Retrospective Analysis of Outcomes in Acute Myeloid Leukemia (AML) Patients Exposed to Intravenous Contrast Prior to Stem Cell Transplantation

PIG-a Gene Expression Deficiency Association with Reduced DNA Damage Checkpoint Response and Activation

Catabolic Flexibility Enhances Drug Resistance but Induces Selective Vulnerability to New Mitochondrial-Targeted Therapeutic Combinations in IDH Mutant Leukemia

Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of Mitochondrial Vulnerability in Acute Myeloid Leukemia

Mitochondrial Dysfunction in Normal and Malignant Hematopoiesis

PRMT1 Mediated FLT3 Methylation As a Therapeutic Vulnerability in FLT3-ITD + AML

Systems Biology Analysis Identifies Targetable Vulnerability Networks to Proteasome Inhibitors in Multiple Myeloma

IDH1 Mutant AML Is Susceptible to Targeting De Novo Lipid Synthesis Independent of 2-Hydroxyglutarate and Has a Distinct Metabolic Profile from IDH2 Mutant AML

Email alerts

ASH Publications

American Society of Hematology